Baxter price target lowered to $30 from $36 at Barclays

Barclays analyst Matt Miksic lowered the firm’s price target on Baxter (BAX) to $30 from $36 and keeps an Overweight rating on the shares. The firm updated the company’s model. The uncertainty related to Baxter’s outlook is “adequately discounted” in the shares, the analyst tells investors in a research note. Barclays expects the company’s Q4 results and 2026 outlook to “help unwind this uncertainty and drive the stock higher.”